WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--July 31, 2006--Merck & Co., Inc. today announced that the New Drug Application (NDA) for MK-0431A, the Company’s investigational oral medicine combining JANUVIA(TM) (sitagliptin phosphate) with metformin for type 2 diabetes, has been accepted for standard review by the U.S. Food and Drug Administration (FDA). Merck expects FDA action on the NDA by the end of March 2007. The Company is also moving forward as planned with regulatory filings in countries outside the United States.
